Connor, Clark & Lunn Investment Management Ltd. Coherus Bio Sciences, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$5.69 - $10.07 $500,845 - $886,381	88,022 New	88,022 $697,000
Q2 2022 Aug 05, 2022	SELL	$5.86 - $13.23 $90,255 - $203,768	-15,402 Reduced 24.14%	48,389 $350,000
Q1 2022 May 12, 2022	BUY	$10.92 - $16.41 $696,597 - $1.05 Million	63,791 New	63,791 $824,000
Q1 2021 May 13, 2021	SELL	$14.42 - $21.39 $204,922 - $303,973	-14,211 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $27,787 - $31,781	-1,678 Reduced 10.56%	14,211 $247,000
Q3 2020 Nov 12, 2020	SELL	$17.41 - $19.89 $6,128 - $7,001	-352 Reduced 2.17%	15,889 $291,000
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $234,357 - $311,177	16,241 New	16,241 $290,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

Black Rock Inc. New York, NY

11.8M
Shares

$18.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.3M
Shares

$17.8 Million
0.0% of portfolio
Rubric Capital Management LP New York, NY

10.4M
Shares

$16.3 Million
0.3% of portfolio
Kohlberg Kravis Roberts & Co. L.P. New York, NY

3.04M
Shares

$4.77 Million
0.18% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.86M
Shares

$4.49 Million
0.0% of portfolio

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account